Non-surgical cryoablation of breast cancer - destruction of diseased
tissue by exposure to freezing temperatures - shows promise as an
alternative to surgery for selected women with early stage invasive
ductal cancer (IDC), according to a new phase II clinical trial
presented this week at the American Society of Breast Surgeons (ASBrS)
Annual Meeting. The study found that 100% of patients' tumors less than
1 cm in size treated with cryoablation had no residual invasive cancer
on pathological examination of the targeted lesion. The success rate for
cancers of any size was 80.5%. For 69% of patients, cryoablation was
successful when defined as no residual IDC or ductal cancer in situ
(DCIS), a precursor to cancer.
"With cryoablation, a woman need not even enter the operating room for
treatment, and he procedure can be as brief as 20 minutes," comments
Rache Simmons, MD, Chief of Breast Surgery at New York
Presbyterian/Weill Cornell Medical Center and lead author of the study.
"Compared to surgery, cryoablation is far less invasive and provides
better cosmetic results, shorter procedure time and faster recovery."
The technique is well-established for treatment of non-cancerous breast
fibroadenomas and has been routinely used for other cancers for some
time. Earlier studies also suggested that cryoablation is an effective
non-surgical treatment for breast cancer in a certain early stage
patients . . .Cont.
LINK TO FULL PRESS KIT FROM AMERICAN SOCIETY OF BREAST SURGEONS ANNUAL
MEETING PRESS CONFERENCE, WITH FULL RELEASE AND ADDITIONAL PRESS
[ Back To NFVZone's Homepage ]